Globela Pharma Private Limited

Globela Pharma Private Limited, established on February 8, 2006, is a privately held pharmaceutical manufacturing company headquartered in Surat, Gujarat, India. The company specializes in the production of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections, catering to both domestic and international markets. Globela Pharma is registered under the Corporate Identification Number (CIN) U24230GJ2006PTC047699.

The company's authorized capital stands at ₹68.5 crore, with a paid-up capital of ₹56.92 crore, reflecting a strong financial foundation. Globela Pharma operates with a dedicated workforce of approximately 201 to 500 employees, as indicated on their LinkedIn profile. Their official website, www.globelapharma.com, provides comprehensive information about their products, services, and global presence.

Globela Pharma's manufacturing facility is strategically located at Plot No. 357 - 358, Road No. 3 GIDC, Sachin, Surat, Gujarat, India. The plant is equipped with state-of-the-art infrastructure and adheres to stringent quality standards, including WHO-GMP and EU-GMP certifications. This facility specializes in the production of high-quality pharmaceutical products, with dedicated units for oncology (anti-cancer) formulations and cephalosporins, ensuring compliance with global regulatory requirements.

The leadership team at Globela Pharma Private Limited comprises experienced professionals committed to driving the company's growth and innovation. Bhanubhai Shambhubhai Vaghashia serves as the Managing Director, having been appointed on February 8, 2006. Urmilaben Bhanubhai Vaghasiya holds the position of Director, with an appointment date of October 25, 2010. Additionally, Priyank Vaghashia and Mayur Anand Sirdesai joined the board as Directors on September 23, 2021, and January 13, 2022, respectively. The company's leadership is further strengthened by Pietro Ermanno Stefanutti, who was appointed as a Director on January 13, 2022.

Globela Pharma Private Limited has established a significant presence in various regulated markets, including the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained approvals from multiple overseas regulatory authorities, such as Myanmar, Sri Lanka, Vietnam, Cambodia, Nigeria, Kenya, and Tanzania, indicating a robust international footprint. While specific details regarding regulatory filings and market access in the U.S., EU, UK, Australia, and Japan are not publicly disclosed, the company's adherence to WHO-GMP and EU-GMP standards suggests a commitment to meeting international regulatory requirements.

Globela Pharma has strategically penetrated emerging markets in Africa, Latin America, and Southeast Asia. The company's products are registered in over 50 countries, including regions such as Venezuela, Chile, Nigeria, Myanmar, Kenya, Philippines, Sri Lanka, Ghana, and Vietnam. This extensive reach is facilitated by the company's WHO-GMP and EU-GMP certifications, which enable access to these markets.

Globela Pharma's geographic strategy demonstrates a balanced approach, with a diversified presence across various regions. The company's significant export value of $3.3 million USD, derived from 139 shipments across nine products in five therapeutic categories, indicates a well-distributed market presence. The top three therapeutic categories—Antifungals (43.8%), Antibiotics (22.7%), and Lipid & Metabolism (17.1%)—reflect a strategic focus on high-demand areas. However, the portfolio concentration, with the top five products accounting for 96.6% of the export value, suggests a potential risk due to over-reliance on a limited product range. To mitigate this, the company may consider diversifying its product portfolio and exploring new markets to reduce concentration risk.

Specific details regarding Globela Pharma's FDA facility registrations, approved Abbreviated New Drug Applications (ANDAs), Drug Master File (DMF) filings, and inspection history are not publicly available. The company's adherence to WHO-GMP and EU-GMP standards indicates a commitment to quality manufacturing practices, which are essential for FDA approvals. However, without explicit information, it is challenging to assess the company's current status with the FDA.

Globela Pharma holds WHO-GMP and EU-GMP certifications, demonstrating compliance with international manufacturing standards. These certifications are crucial for accessing global markets and ensuring product quality. The company's manufacturing facility is also ISO 9001:2015 certified, reflecting a commitment to quality management systems.

Globela Pharma operates under the regulatory framework of the Central Drugs Standard Control Organisation (CDSCO) in India. The company's manufacturing facility is WHO-GMP and EU-GMP certified, indicating compliance with international standards. Specific details regarding CDSCO manufacturing licenses, state drug controller approvals, and export No Objection Certificates (NOCs) are not publicly disclosed. However, the company's adherence to global standards suggests a strong regulatory standing within India.

As of March 28, 2026, there are no publicly available records of Form 483 observations, warning letters, or import alerts issued to Globela Pharma Private Limited. The company's adherence to WHO-GMP and EU-GMP standards, along with certifications from various overseas regulatory authorities, indicates a proactive approach to compliance and quality assurance.

Globela Pharma operates in a competitive landscape with several key players in the pharmaceutical manufacturing sector. Top competitors include Sun Pharmaceutical Industries Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Ltd., Cipla Ltd., Zydus Lifesciences Ltd., and Lupin Ltd. While Globela Pharma's export value of $3.3 million USD is modest compared to these industry giants, the company's focus on high-quality formulations and adherence to international standards positions it as a reliable supplier in niche markets. The company's specialization in oncology and cephalosporin products further differentiates it from competitors.

Globela Pharma's key differentiators include its specialized facilities for oncology and cephalosporin formulations, adherence to WHO-GMP and EU-GMP standards, and a strong in-house R&D center approved by the Department of Scientific and Industrial Research (DSIR). These factors enable the company to offer high-quality, affordable pharmaceutical solutions tailored to the needs of diverse markets.

Globela Pharma's current strategic direction focuses on manufacturing high-quality pharmaceutical formulations, with a particular emphasis on oncology and cephalosporin products. The company's adherence to international standards and certifications positions it well for future growth in both existing and new markets. To enhance its strategic position, the company may consider diversifying its product portfolio and expanding its presence in emerging markets.

Globela Pharma has demonstrated a consistent track record in pharmaceutical manufacturing, with an export value of $3.3 million USD from 139 shipments across nine products in five therapeutic categories. The company's adherence to WHO-GMP and EU-GMP standards, along with certifications from various overseas regulatory authorities, indicates reliability and commitment to quality. The company's specialization in oncology and cephalosporin products further underscores its expertise in these areas.

Importers should verify the following certifications when considering Globela Pharma as a supplier:

• WHO-GMP Certification: Ensures compliance with World Health Organization's Good Manufacturing Practices. Verification can be done through the WHO's official website or by contacting the company directly.

• EU-GMP Certification: Confirms adherence to European Union's Good Manufacturing Practices. Verification can be conducted through the European Medicines Agency (EMA) or by reaching out to the company.

• ISO 9001:2015 Certification: Indicates a commitment to quality management systems. Verification can be performed through the International Organization for Standardization (ISO) or by contacting the company.

When conducting due diligence on Globela Pharma